AstraZeneca Pharma India Limited AI Stock Analysis
Want to see IN:ASTRAZEN full AI Analyst Report?
AstraZeneca Pharma India Limited (ASTRAZEN) AI Stock Analysis
AstraZeneca Pharma India Limited
(NSE:ASTRAZEN)
The stock is heavily weighed down by a stretched valuation (P/E over 105) and severe bearish technical momentum across all timeframes. While supported by steady revenue growth and a highly stable balance sheet, sharply deteriorating cash flows and steep margin compression prevent a higher rating.
AstraZeneca Pharma India Limited (ASTRAZEN) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 162.68B
- Dividend Yield
- 0.55%
- Average Volume (3M)
- 551
- Price to Earnings (P/E)
- 91.5
- Beta (1Y)
- 0.68
- Revenue Growth
- 29.70%
- EPS Growth
- -10.76%
- Country
- India
- Employees
- 760
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
AstraZeneca Pharma India Limited Business Overview & Revenue Model
Company Description
AstraZeneca Pharma India Limited operates as a biopharmaceutical entity, engaged in the development, production, and global commercialization of pharmaceutical products, serving both the Indian domestic market and international clientele. The company...
AstraZeneca Pharma India Limited Financial Statement Overview
Summary
AstraZeneca Pharma India presents a mixed picture. It boasts strong top-line growth and a fortress balance sheet with low leverage. However, severe deterioration in cash flow generation and steep gross margin compression represent notable underlying risks.
Income Statement
72PositiveBalance Sheet
88Very PositiveCash Flow
42Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 24.32B | 22.76B | 17.13B | 12.96B | 10.03B | 8.06B |
| Gross Profit | 7.64B | 6.02B | 7.13B | 6.22B | 5.78B | 4.48B |
| EBITDA | 2.42B | 2.85B | 1.98B | 2.36B | 1.51B | 1.01B |
| Net Income | 1.70B | 1.88B | 1.16B | 1.62B | 992.90M | 616.00M |
Balance Sheet | ||||||
| Total Assets | 0 | 19.89B | 15.18B | 10.78B | 9.85B | 8.57B |
| Cash, Cash Equivalents and Short-Term Investments | 4.48B | 4.49B | 5.53B | 5.06B | 5.00B | 4.48B |
| Total Debt | 0 | 1.11B | 357.30M | 45.90M | 72.10M | 86.30M |
| Total Liabilities | -8.73B | 11.16B | 7.48B | 3.66B | 3.96B | 3.45B |
| Stockholders Equity | 8.73B | 8.73B | 7.70B | 7.12B | 5.89B | 5.11B |
Cash Flow | ||||||
| Free Cash Flow | -660.20M | 32.10M | 636.10M | 171.10M | 497.70M | 911.80M |
| Operating Cash Flow | -657.30M | 68.20M | 653.60M | 278.70M | 582.90M | 1.01B |
| Investing Cash Flow | 135.40M | -33.40M | 308.00M | 217.40M | 181.10M | 47.40M |
| Financing Cash Flow | -845.60M | -919.00M | -655.90M | -443.80M | -244.80M | -94.60M |
AstraZeneca Pharma India Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ASTRAZEN, the sentiment is Positive. The current price of 6511.10 is above the 20-day moving average (MA) of 6183.46, above the 50-day MA of 6394.75, and below the 200-day MA of 7827.47, indicating a neutral trend. The MACD of 30.97 indicates Negative momentum. The RSI at 61.39 is Neutral, neither overbought nor oversold. The STOCH value of 54.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:ASTRAZEN.
AstraZeneca Pharma India Limited Peers Comparison
Overall Rating
IN:LUPIN77Outperform
IN:TORNTPHARM69Neutral
IN:GLENMARK66Neutral
IN:SUNPHARMA64Neutral
IN:DRREDDY63Neutral- IN:ASTRAZEN53Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| IN:LUPIN | 77Outperform | INR 920.07B | 17.76 | ― | 0.89% | 24.22% | 20.24% |
| IN:TORNTPHARM | 69Neutral | INR 1.82T | 78.00 | ― | 0.31% | 42.06% | -3.48% |
| IN:GLENMARK | 66Neutral | INR 756.33B | 52.05 | ― | 0.19% | -0.11% | 43.72% |
| IN:SUNPHARMA | 64Neutral | INR 4.57T | 41.63 | ― | 0.84% | 12.13% | 4.94% |
| IN:DRREDDY | 63Neutral | INR 1.15T | 40.98 | ― | 0.58% | -3.60% | -52.23% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| IN:ASTRAZEN | 53Neutral | INR 162.81B | 91.53 | ― | 0.55% | 29.70% | -10.76% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:ASTRAZEN | AstraZeneca Pharma India Limited | 6511.10 | -2603.26 | -28.56% | |
| IN:DRREDDY | Dr. Reddy's Laboratories Ltd. | 1376.00 | 138.89 | 11.23% | |
| IN:GLENMARK | Glenmark Pharmaceuticals Limited | 2675.00 | 779.38 | 41.12% | |
| IN:LUPIN | Lupin Limited | 2021.00 | -19.30 | -0.95% | |
| IN:SUNPHARMA | Sun Pharmaceutical Industries Limited | 1896.00 | 155.50 | 8.93% | |
| IN:TORNTPHARM | Torrent Pharmaceuticals Ltd | 4763.00 | 957.01 | 25.14% |
AstraZeneca Pharma India Limited Corporate Events
Delhi High Court Restrains NPPA Action Against AstraZeneca
AstraZeneca Pharma India Limited operates in the pharmaceutical industry and markets prescription medicines in India, including respiratory inhalation therapies such as Symbicort Turbuhaler. Its portfolio serves healthcare providers and patients in t...
AstraZeneca Pharma India Confirms SEBI Dematerialization Compliance for Q2 FY2026
AstraZeneca Pharma India Limited has submitted a certificate to BSE and NSE confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026. The certificate, issued by...
Delhi High Court Grants AstraZeneca India Interim Relief in NPPA Drug Pricing Dispute
AstraZeneca Pharma India Limited has informed the stock exchanges that the Delhi High Court has granted an interim stay on a National Pharmaceutical Pricing Authority demand notice alleging overcharging on Betaloc-50 tablets. The notice claimed the c...
AstraZeneca Pharma India Discloses Unsolicited ESG Rating from Crisil
AstraZeneca Pharma India Limited disclosed that Crisil ESG Ratings & Analytics has assigned it an Environmental, Social and Governance score of 57, based solely on publicly available information. The company clarified it did not engage Crisil for thi...
AstraZeneca Pharma India Plans Virtual Meeting With Institutional Investor
AstraZeneca Pharma India Limited has scheduled a virtual one-on-one meeting with an institutional investor on August 26, 2026, in line with regulatory requirements for disclosure of analyst and investor interactions. The company notes that the date m...
AstraZeneca Pharma India Schedules Virtual Meet with Institutional Investor
AstraZeneca Pharma India has announced that it will hold a virtual one-on-one meeting with an institutional investor on August 19, 2026, as part of its ongoing engagement with the analyst and investor community. The company noted that the schedule ma...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 28, 2026